A New Treatment for BPDCN is on Track for EU Approval
source: pixabay.com

A New Treatment for BPDCN is on Track for EU Approval

According to a story from PR Newswire, the pharmaceutical and diagnostics company The Menarini Group recently announced that its drug tagraxofsup (marketed as Elzonris) has a received a positive opinion…

Continue Reading A New Treatment for BPDCN is on Track for EU Approval

FDA Approves an Experimental Treatment of Various Blood Malignancies for Clinical Trials

According to a story from First World Pharma, the biopharmaceutical company Mustang Bio, Inc. recently announced that the US Food and Drug Administration (FDA) has approved their investigational new drug…

Continue Reading FDA Approves an Experimental Treatment of Various Blood Malignancies for Clinical Trials
This Drug Could be the First Approved Treatment for a Rare Blood Cancer
allinonemovie / Pixabay

This Drug Could be the First Approved Treatment for a Rare Blood Cancer

According to a story from OncLive, the results of a Phase II trial for an experimental drug called SL-401 showed that the product could be a potentially effective treatment for…

Continue Reading This Drug Could be the First Approved Treatment for a Rare Blood Cancer

The FDA Have Granted Priority Review to Elzonris for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

  A Biologics License Application for ElzonrisTM (also known as tagraxofusp and SL-401) for the treatment of blastic plasmacytoid dendritic cell neoplasm has been accepted for filing by the United States FDA.…

Continue Reading The FDA Have Granted Priority Review to Elzonris for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
Encouraging Results Have Been Announced From a Trial of an Investigational Treatment For BPDCN
kkolosov / Pixabay

Encouraging Results Have Been Announced From a Trial of an Investigational Treatment For BPDCN

Results from research into an experimental therapy called SL-401 for the treatment of patients with blastic plasmacytoid dendritic cell neoplasm have been shared at the Congress of the European Haematology…

Continue Reading Encouraging Results Have Been Announced From a Trial of an Investigational Treatment For BPDCN